How to manage conflicts of interest with industry?

References

• Alonso-Zalvidar R. Drug makers set lobbying record. Los Angeles Times April 3, 2007
   Google Scholar
• American Medical Student Association. Pharmfree scorecard. 2007, www.amsa.org. Accessed 24 May 2007
   Google Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. Journal of the American Medical Association 2003; 289: 454–465
   PubMed Web of Science ®Google Scholar
• Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health industry practices that create conflicts of interest. Journal of the American Medical Association 2006; 295: 429–433
   PubMed Web of Science ®Google Scholar
• Brewin TB. How much ethics is needed to make a good doctor?. Lancet 1993; 341: 161–163
   PubMedGoogle Scholar
• Brodkey AC. The role of the pharmaceutical industry in teaching psychopharmacology: A growing problem. Academic Psychiatry 2005; 29: 222–229
   PubMedGoogle Scholar
• Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. New England Journal of Medicine 2007; 356: 1742–1750
   PubMed Web of Science ®Google Scholar
• Chren M-M, Landefeld CS, Murray THC. Doctors, drug companies, and gifts. Journal of the American Medical Association 1989; 262: 3448–3451
   PubMed Web of Science ®Google Scholar
• Davis K, Schoen C, Schoenbaum SC, Audet AJ, Doty MM, Holmgren AL, et al. Mirror, mirror on the wall: An update on the quality of American health care through the patient's lens. Commonwealth Fund, New York 2006
   Google Scholar
• Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. Journal of the American Medical Association 2003; 290: 252–255
   PubMed Web of Science ®Google Scholar
• DeAngelis CD, Drazen JM, Frizelle FA, Hague C, Hoey J, Horton R, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Journal of the American Medical Association 2005; 293: 2927–2929
   Google Scholar
• Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 2007; 357: 673–681
   PubMed Web of Science ®Google Scholar
• Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lamsdale T. Encounters with pharmaceutical sales representatives among practicing internists. American Journal of Medicine 1999; 107: 149–152
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Prescription Drug User Fee Act (PDU-FA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. Food and Drug Administration, Washington DC 2005
   Google Scholar
• Harris G. Psychiatrists top list of drug maker gifts. New York Times June 27, 2007; A14
   Google Scholar
• Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry 2003; 183: 22–27
   PubMed Web of Science ®Google Scholar
• Hennessy S, Strom BL. PDUFA reauthorization–drug safety's golden moment of opportunity?. New England Journal of Medicine 2007; 356: 1703–1704
   PubMedGoogle Scholar
• Hodges B. Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Journal 1995; 153: 553–559
   Web of Science ®Google Scholar
• Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academics Press, Washington DC 2006
   Google Scholar
• Katz D, Caplan AL, Merz JE. All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics 2003; 3: 39–46
   PubMed Web of Science ®Google Scholar
• Kaufman M. Former FDA chief illegally held stocks. Washington Post 2006; October 17: A19
   Google Scholar
• Keitz SA, Stechuchak KM, Grambow SC, Koropchak CM, Tulsky JA. Behind closed doors. Archives of Internal Medicine 2007; 167: 445–452
   PubMedGoogle Scholar
• Kjaergard LL, Als-Nieson B. Association between competing interests and authors’ conclusions: Epidemiologic study of randomized clinical trials published in the. BMJ. British Medical Journal 2002; 325: 249–252
   PubMedGoogle Scholar
• Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants. Journal of the American Medical Association 2005; 293: 1995–2002
   PubMed Web of Science ®Google Scholar
• Lasser KE, Allen, P.D. Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 2002; 287: 2215–2220
   PubMed Web of Science ®Google Scholar
• Light DW, Lexchin J. Foreign free riders and the high price of US medicines. British Medical Journal 2005; 331: 958–960
   PubMed Web of Science ®Google Scholar
• Mathews AW. At medical journals, writers paid by industry play big role 2005, The Wall Street Journal, December 13, A1
   Google Scholar
• Mathews AW. Drug firms use financial clout to push agenda at FDA 2006, The Wall Street Journal, September 1, A1
   Google Scholar
• Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal 2003; 169: 405–412
   PubMed Web of Science ®Google Scholar
• Mohl PC. Psychiatric training program engagement with the pharmaceutical industry: An educational issue, not strictly an ethical one. Academic Psychiatry 2005; 29: 215–221
   PubMedGoogle Scholar
• Morgenson G. Fair game: More $200 million parachutes? Don’t be shocked January 7, 2007, The New York Times
   Google Scholar
• National Institutes of Health. Extramural data and trends. National Institutes of Health, Bethesda, MD 2000
   Google Scholar
• Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Academic Medicine 1997; 72: 916–918
   PubMed Web of Science ®Google Scholar
• Schwartz RK, Soumerai SB, Avron J. Physician motivations for nonscientific drug prescribing. Social Science and Medicine 1989; 28: 577–582
   PubMed Web of Science ®Google Scholar
• Shaughnessy AF, Slawson DC. Pharmaceutical representatives. British Medical Journal 1996; 312: 1494
   PubMedGoogle Scholar
• Stagnitti MN. Trends in Outpatient Prescription Drug Utilization and Expenditures: 1997 and 2004 2007, Statistical Brief No. 168. Rockville, MD: Agency for Healthcare Research and Quality
   Google Scholar
• Steinbrook R. Commercial support and continuing medical education. New England Journal of Medicine 2005; 352: 534–535
   PubMedGoogle Scholar
• Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. American Journal of Medicine 2001; 110: 551–557
   PubMed Web of Science ®Google Scholar
• Studdert DM, Mello MM, Brennan JA. Financial conflicts of interest in physicians’ relationships with the pharmaceutical industry - self-regulation in the shadow of federal prosecution. New England Journal of Medicine 2004; 351: 1891–1900
   PubMedGoogle Scholar
• Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. Journal of the American Medical Association 2000; 283: 373–380
   PubMed Web of Science ®Google Scholar
• Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. Journal of the American Medical Association 1995; 273: 1296–1298
   PubMed Web of Science ®Google Scholar
• Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Affairs 2005; 24: 195–205
   PubMed Web of Science ®Google Scholar